In a new strategic partnership with Salus Optima, IFF are developing a data driven personalized nutrition, health and wellness platform targeting metabolic health
Posted:
1 in 4 adults worldwide are affected by metabolic health issues such as obesity, pre-diabetes, high cholesterol, and pre-hypertension. IFF announced its plans for accelerated entry into the personalized nutrition sector through a strategic partnership with Salus Optima, a British-based, digitally-enabled personalized nutrition, health and wellness company. Read more here.
As we step into 2025, we’re excited to continue innovating, collaborating, and transforming healthcare together.
This year, let’s work towards improving health and well-being across the UK and beyond.
Mark your calendars!
Join us on 8th & 9th December 2025…
Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program.
Read the full article in…